Method for separating and determining impurities in fenerenone intermediate Z2 by HPLC (High Performance Liquid Chromatography) method

Through HPLC method and gradient elution technology, the non-nelinone intermediate Z2 and its impurities were successfully isolated and detected, solving the problem that the existing technology could not be effectively detected, and achieving efficient and accurate drug quality control.

CN119064495APending Publication Date: 2024-12-03CHONGQING HUAPONT PHARMA
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411175796.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art cannot effectively isolate and detect the non-nelinone intermediate Z2 and its related impurities, affecting the quality and safety of the drug.

Method used

Using HPLC method, using octadecylsilane bonded silica gel as chromatographic column filler, trifluoroacetic acid aqueous solution and organic solvent as mobile phase, the fenellinone intermediate Z2 and its impurities were separated by gradient elution, and ultraviolet detection was carried out. The device performs detection.

Benefits of technology

The efficient separation and identification of the non-nelinone intermediate Z2 and its impurities is achieved, and the quantification limit is low. It can be separated and detected with concentrations as low as 0.07-0.09μg/ml within 60 minutes, improving the quality and safety of the drug sex.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119064495A_ABST
    Figure CN119064495A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of pharmaceutical analysis, and particularly relates to a method for separating and determining impurities in a fenerenone intermediate Z2 by an HPLC (High Performance Liquid Chromatography) method. The impurity is any one or more of an impurity Z2a, an impurity SM1, an impurity Z1c, an impurity Z1, an impurity Z2d, an impurity Z2e and an impurity Z2b. According to the method, octadecyl silane bonded silica gel is adopted as a chromatographic column filler, a trifluoroacetic acid aqueous solution is adopted as a mobile phase A, an organic solvent is adopted as a mobile phase B, and the main component fenerenone intermediate Z2 and impurities thereof in a sample to be detected are separated through gradient elution; detecting in a detector to obtain a chromatogram; and calculating the content of each impurity by adopting a correction factor-added principal component self-contrast method and / or an external standard method. The method successfully realizes simultaneous separation and determination of seven impurities in the fenerenone intermediate Z2, has the advantages of high sensitivity, strong practicability and accurate and reliable result, and has important significance for quality control of the fenerenone Z2.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug analysis, and in particular relates to a method for separating and determining impurities in a finerenone intermediate Z2 by HPLC. Background Art

[0002] Finerenone (BAY94-8862), as a non-steroidal, selective mineralocorticoid receptor antagonist, has dual cardiorenal protective effects on diabetic nephropathy. Finerenone protects kidney and heart function by blocking excessive activation of mineralocorticoid receptors (MR), reducing inflammation and fibrosis. The drug has shown good efficacy and safety in the treatment of chronic kidney disease associated with type 2 diabetes. To ensure the safety and effectiveness of drugs, the impurity content needs to be strictly controlled at every stage of drug research and development to ensure the quality and safety of the final product.

[0003] Finerenone intermediate Z2 is a key intermediate in the synthesis of finerenone. Studying and controlling its impurity content is of great significance to improving the quality of finerenone drugs. Studies have found that the following impurities may exist in finerenone intermediate Z2: Impurity Z 2a , impurity SM1, impurity Z 1c , impurity Z2, impurity Z1, impurity Z 2d 、Impurity Z 2e 、Impurity Z 2b 、Impurity SM3、Impurity SM 3a 、Impurity Z 2c ; Its structural formula is shown in Formula I to Formula XI. These impurities will affect the quality of finerenone intermediate Z2, and further affect the quality of finerenone preparation products. However, there is no existing literature or patent information reporting on the analysis method of finerenone intermediate Z2 and its related impurities.

[0004]

[0005]

[0006] There are few reports on the analysis methods of finerenone and its related substances in the prior art. It was found that patent CN117630224A discloses a method for separating and determining the enantiomers of finerenone by HPLC, which uses a silica gel surface coated with amylose-tris (3,5-dimethylphenylcarbamate) as a filler, uses lower alkanes as mobile phase A and lower alcohols as mobile phase B, performs isocratic elution, and uses an ultraviolet detector for detection. However, this method cannot effectively separate and detect the finerenone intermediate Z2 and its related impurities.

[0007] Therefore, it is necessary to establish a new method to detect finerenone intermediate Z2 and its related impurities to improve the quality of finerenone intermediate Z2 and finerenone preparation products. Summary of the invention

[0008] In view of this, one of the objects of the present invention is to provide a method for separating a finerenone intermediate Z2 and its impurities using an HPLC method, wherein the method can achieve effective separation of the finerenone intermediate Z2 and its impurities within 60 minutes or more.

[0009] To achieve the above object, the present invention adopts the following technical solutions:

[0010] The method for separating finerenone intermediate Z2 and its impurities by HPLC method comprises the following steps:

[0011] (1) preparing a sample solution to be tested; the sample solution to be tested comprises the finerenone intermediate Z2 and its impurities; the impurities include impurity Z 2a , impurity SM1, impurity Z 1c , impurity Z1, impurity Z 2d 、Impurity Z 2e 、Impurity Z 2b Any one or more of;

[0012] (2) using octadecylsilane bonded silica gel as a chromatographic column filler, using trifluoroacetic acid aqueous solution as mobile phase A, using an organic solvent as mobile phase B, and separating the main component phenerenone intermediate Z2 and its impurities in the sample to be tested by gradient elution;

[0013] The structural formula of the finerenone intermediate Z2 is shown in Formula I. 2a The structural formula of the impurity SM1 is shown in Formula II, the structural formula of the impurity Z is shown in Formula III, 1c The structural formula of the impurity Z1 is shown in Formula Ⅴ, and the impurity Z 2d The structural formula of is shown in Formula VI, the impurity Z 2e The structural formula of is shown in Formula VII, the impurity Z 2b The structural formula is shown in Formula VIII;

[0014]

[0015]

[0016] Further, the sample to be tested is a composition to be tested; the composition to be tested comprises finerenone intermediate Z2, related substances, and impurity Z 2a , impurity SM1, impurity Z 1c , impurity Z1, impurity Z 2d、Impurity Z 2e 、Impurity Z 2b Any one or more of; the related substances include impurities SM3, impurities SM 3a 、Impurity Z 2c Any one or more of; the structural formula of the impurity SM3 is shown in Formula IX, the impurity SM 3a The structural formula of is shown in Formula X, impurity Z 2c The structural formula is shown in Formula Ⅺ;

[0017]

[0018] Furthermore, the method can be used to separate impurities in finerenone intermediate Z2 and its related substances.

[0019] Further, the program of the gradient elution is set as follows:

[0020] 0min, the volume ratio of the mobile phase A to the mobile phase B is 70-90:30-10;

[0021] 3min, the volume ratio of the mobile phase A to the mobile phase B is 70-90:30-10;

[0022] 27min, the volume ratio of the mobile phase A to the mobile phase B is 55-65:45-35;

[0023] 45min, the volume ratio of the mobile phase A to the mobile phase B is 30-50:70-50;

[0024] 50min, the volume ratio of the mobile phase A to the mobile phase B is 30-50:70-50;

[0025] 50.1min, the volume ratio of the mobile phase A to the mobile phase B is 70-90:30-10;

[0026] 60min, the volume ratio of the mobile phase A to the mobile phase B is 70-90:30-10.

[0027] Preferably, the gradient elution program is set as follows:

[0028] 0min, the volume ratio of the mobile phase A to the mobile phase B is 78-82:22-18;

[0029] 3min, the volume ratio of the mobile phase A to the mobile phase B is 78-82:22-18;

[0030] 27min, the volume ratio of the mobile phase A to the mobile phase B is 62:38;

[0031] 45min, the volume ratio of the mobile phase A to the mobile phase B is 40:60;

[0032] 50min, the volume ratio of the mobile phase A to the mobile phase B is 40:60;

[0033] 50.1min, the volume ratio of the mobile phase A to the mobile phase B is 78-82:22-18;

[0034] 60min, the volume ratio of the mobile phase A to the mobile phase B is 78-82:22-18.

[0035] Most preferably, the gradient elution program is set as follows:

[0036] 0min, the volume ratio of the mobile phase A to the mobile phase B is 80:20;

[0037] 3min, the volume ratio of the mobile phase A to the mobile phase B is 80:20;

[0038] 27min, the volume ratio of the mobile phase A to the mobile phase B is 62:38;

[0039] 45min, the volume ratio of the mobile phase A to the mobile phase B is 40:60;

[0040] 50min, the volume ratio of the mobile phase A to the mobile phase B is 40:60;

[0041] 50.1min, the volume ratio of the mobile phase A to the mobile phase B is 80:20;

[0042] 60min, the volume ratio of the mobile phase A to the mobile phase B is 80:20.

[0043] Furthermore, the concentration of the trifluoroacetic acid aqueous solution is 0.05%-0.15%, preferably 0.09%-0.11%, and most preferably 0.1%; and the organic solvent is methanol.

[0044] Furthermore, the flow rate of the mobile phase is 0.8-1.5 ml / min, preferably 1.0 ml / min-1.2 ml / min, and most preferably 1.1 ml / min; the column temperature of the chromatographic column is 30°C-40°C, preferably 33°C-37°C, and most preferably 35°C; the injector temperature is 3°C-7°C, preferably 5°C.

[0045] Preferably, the running time is 60 minutes.

[0046] Preferably, the chromatographic column has a specification of 4.6 mm×150 mm 3 μm, and Shim-pack FC-ODS, 4.6 mm×150 mm 3 μm, is preferred.

[0047] Preferably, the injection volume is 10 μl.

[0048] Preferably, in step (1), the sample preparation solvent is an acetonitrile aqueous solution with a concentration of 50%, prepared from acetonitrile and water in a volume ratio of 50:50.

[0049] Preferably, the concentration of the sample solution to be tested is 1 mg / ml.

[0050] The second object of the present invention is to provide a method for identifying finerenone intermediate Z2 and its impurities. The method has a low detection limit and can effectively identify impurities in samples with a concentration as low as 0.07-0.09 μg / ml.

[0051] To achieve the above object, the present invention adopts the following technical solutions:

[0052] The method for identifying finerenone intermediate Z2 and its impurities comprises the following steps: separating finerenone intermediate Z2 and its impurities by the aforementioned method; entering into a detector for detection to obtain a chromatogram; and judging whether the test sample contains finerenone intermediate Z2 and its impurities by comparing the chromatographic behaviors of the test sample and the reference sample.

[0053] Furthermore, the detection wavelength of the detector is 240nm-280nm, preferably 260nm.

[0054] Further, using finerenone intermediate Z2 as the reference peak, the peak with a relative retention time of 0.73±0.2 was judged to be impurity Z 2a The relative retention time of 0.84±0.2 was judged as impurity SM1, and the relative retention time of 0.93±0.2 was judged as impurity Z. 1c The relative retention time of 1.17±0.2 was judged as impurity Z1, and the relative retention time of 1.21±0.2 was judged as impurity Z 2d The relative retention time of 1.41±0.2 is judged as impurity Z 2e The relative retention time of 1.46±0.2 is judged as impurity Z 2b .

[0055] Furthermore, the residue with a retention time of 27.3±0.5 was determined to be the intermediate Z2 of nelenone, and the residue with a retention time of 19.6±0.5 was determined to be the impurity Z 2a The impurity with a retention time of 22.4±0.5 was judged to be impurity SM1, and the impurity with a retention time of 25.0±0.5 was judged to be impurity Z. 1cThe retention time of 31.4±0.5 was judged as impurity Z1, and the retention time of 32.6±0.5 was judged as impurity Z 2d , the retention time of 37.9±0.5 is judged as impurity Z 2e , the retention time of 39.3±0.5 is judged as impurity Z 2b .

[0056] The components can be identified based on retention time or relative retention time.

[0057] The third object of the present invention is to provide a method for determining finerenone intermediate Z2 and its impurities, which has a low limit of quantification and can effectively detect impurity content in samples as low as 0.2-0.3 μg / ml.

[0058] To achieve the above object, the present invention adopts the following technical solutions:

[0059] The method for determining finerenone intermediate Z2 and its impurities comprises the following steps:

[0060] (1) separating and detecting the finerenone intermediate Z2 and its impurities using the aforementioned identification method to obtain a chromatogram;

[0061] (2) Based on the chromatogram obtained in step (1), the content of each impurity is calculated by peak area using the main component self-reference method with a correction factor and / or the external standard method.

[0062] Furthermore, the solution to be tested includes, in addition to the sample solution, a control solution and a system suitability solution.

[0063] Preferably, the concentration of the control solution is 5 μg / ml.

[0064] As a preferred technical solution, the method comprises the following steps:

[0065] 1. Prepare a solvent by mixing acetonitrile and water in a volume ratio of 50:50;

[0066] 2. Take an appropriate amount of this product, weigh it accurately, add a solvent and ultrasonicate to dissolve it and dilute it to make a solution containing about 1 mg per 1 ml as the sample solution;

[0067] 3. Accurately measure an appropriate amount of sample solution, add solvent and quantitatively dilute it to make a solution containing about 5 μg per 1 ml as the control solution;

[0068] 4. Take Z2 system suitability reference (containing impurity Z 2a , impurity SM1, impurity Z 1c , impurity Z1, impurity Z 2d 、Impurity Z 2e 、Impurity Z 2b) in appropriate amount, dissolve with sonication in a solvent and dilute to make a solution containing about 1 mg per 1 ml as the system suitability solution;

[0069] 5. Take the above-mentioned system suitability solution, sample solution and control solution, inject them into the liquid chromatograph in sequence, detect them according to the above-mentioned chromatographic conditions, and obtain a chromatogram; calculate the content of each impurity by the main component self-reference method with correction factor and / or the external standard method.

[0070] Furthermore, in the system suitability solution chromatogram, the peak order is impurity Z 2a , impurity SM1, impurity Z 1c , Z2, impurity Z1, impurity Z 2d 、Impurity Z 2e 、Impurity Z 2b , the separation between each component peak should meet the requirements.

[0071] Furthermore, the content of each impurity is calculated by the principal component self-comparison method with a correction factor; the impurity Z 2a The correction factor of impurity SM1 is 0.58, and the correction factor of impurity Z 1c The correction factor of impurity Z1 is 1.6, and the correction factor of impurity Z 2b The correction factor is 1.2, and the impurity Z 2d The correction factor is 1.0, and the impurity Z 2e The correction factor is 1.0.

[0072] Furthermore, if the impurity Z in the test product 2a , impurity SM1, impurity Z 1c , impurity Z1, impurity Z 2b 、Impurity Z 2d and impurity Z 2e If the impurity Z in the test sample is less than or equal to 0.3 times the main peak area of ​​the control solution (0.15%), the area of ​​other single impurity peaks is less than or equal to the main peak area of ​​the control solution (0.5%), and the total amount of impurities is not more than 2.0%, it means that the test sample is qualified; on the contrary, if the impurity Z in the test sample is 2a , impurity SM1, impurity Z 1c , impurity Z1, impurity Z 2b 、Impurity Z 2d and impurity Z 2e If the peak area of ​​the impurity is greater than 0.3 times (0.15%) of the main peak area of ​​the control solution, or the peak area of ​​other individual impurities is greater than the main peak area of ​​the control solution (0.5%), or the total amount of impurities is greater than 2.0%, it means that the test product is unqualified.

[0073] The beneficial effects of the present invention are:

[0074] 1. Used to separate impurity Z from phenerenone intermediate Z22a , impurity SM1, impurity Z 1c , impurity Z2, impurity Z1, impurity Z 2d 、Impurity Z 2e 、Impurity Z 2b The method for determining its content has not been reported in the literature. This method belongs to a self-built high performance liquid chromatography method, which has the advantages of being simple, rapid, highly accurate, durable, and reproducible.

[0075] 2. This method realizes the determination of impurity Z in finerenone intermediate Z2 in a set of HPLC methods. 2a , impurity SM1, impurity Z 1c , impurity Z2, impurity Z1, impurity Z 2d 、Impurity Z 2e 、Impurity Z 2b A total of 7 impurities were effectively separated. The method had good specificity and was not affected by blanks, known impurities (such as impurity SM3, impurity SM 3a 、Impurity Z 2c etc.) and other unknown impurities, the separation between known impurities is greater than 2.0, which meets the requirements of relevant substances.

[0076] 3. The HPLC analysis method for 7 impurities in the finerenone intermediate Z2 provided by the present invention can simultaneously separate the 7 impurities in the finerenone intermediate Z2 in a relatively short time, and the separation time only takes 60 minutes.

[0077] 4. The method of the present invention has the characteristics of high sensitivity, impurity Z 2a The quantitative limit of impurity Z was as low as 0.246μg / ml, and the detection limit was as low as 0.086μg / ml; the quantitative limit of impurity SM1 was as low as 0.256μg / ml, and the detection limit was as low as 0.089μg / ml; 1c The quantitative limit of impurity Z1 was as low as 0.251 μg / ml, and the detection limit was as low as 0.088 μg / ml; the quantitative limit of impurity Z2 was as low as 0.202 μg / ml, and the detection limit was as low as 0.071 μg / ml; the quantitative limit of impurity Z1 was as low as 0.251 μg / ml, and the detection limit was as low as 0.088 μg / ml; the quantitative limit of impurity Z 2d The quantitative limit concentration is as low as 0.226μg / ml, and the detection limit concentration is as low as 0.079μg / ml; impurity Z 2e The quantitative limit concentration is as low as 0.246μg / ml, and the detection limit concentration is as low as 0.086μg / ml; impurity Z 2b The limit of quantification was as low as 0.253 μg / ml, and the limit of detection was as low as 0.089 μg / ml. BRIEF DESCRIPTION OF THE DRAWINGS

[0078] Figure 1It is the HPLC chart of the blank solution in the specificity experiment;

[0079] Figure 2 It is the HPLC chart of the mixed solution in the specificity experiment;

[0080] Figure 3 This is the HPLC graph of the test solution in the specificity and accuracy experiment;

[0081] Figure 4 It is the HPLC chart of the system suitability solution in the system suitability verification experiment;

[0082] Figure 5 It is the HPLC chart of the quantitative limit solution in the quantitative limit experiment;

[0083] Figure 6 It is the HPLC chart of the detection limit solution in the detection limit experiment;

[0084] Figure 7 This is the HPLC chart of the reference solution in the accuracy experiment;

[0085] Figure 8 This is the HPLC graph of 80% of the spiked solution in the accuracy experiment;

[0086] Fig. 9 This is the HPLC graph of the 100% spiked solution in the accuracy experiment;

[0087] Fig.10 This is the HPLC graph of the 120% spiked solution in the accuracy experiment;

[0088] Fig.11 This is the HPLC graph of the mixed solution under normal conditions in the durability experiment;

[0089] Fig.12 This is the HPLC chart of the mixed solution when the concentration of trifluoroacetic acid is 0.09% in the durability experiment;

[0090] Fig.13 This is the HPLC chart of the mixed solution when the concentration of trifluoroacetic acid is 0.11% in the durability experiment;

[0091] Fig.14 This is the HPLC graph of the mixed solution when the organic phase ratio in the mobile phase is 18% in the durability experiment;

[0092] Fig.15 This is the HPLC graph of the mixed solution when the organic phase ratio in the mobile phase is 22% in the durability experiment;

[0093] Fig.16 This is the HPLC graph of the mixed solution when the column temperature is 33°C in the durability experiment;

[0094] Fig.17 This is the HPLC graph of the mixed solution when the column temperature is 37°C in the durability experiment;

[0095] Fig.18 This is the HPLC graph of the mixed solution at a flow rate of 1.0 ml / min in the durability experiment;

[0096] Fig.19 This is the HPLC chart of the mixed solution at a flow rate of 1.2 ml / min in the durability experiment. DETAILED DESCRIPTION

[0097] The technical solution of the present invention will be further described clearly and completely in conjunction with specific embodiments below. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Therefore, based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work belong to the protection scope of the present invention.

[0098] The present invention provides a method for detecting impurity Z in finerenone intermediate Z2. 2a , impurity SM1, impurity Z 1c , impurity Z1, impurity Z 2d 、Impurity Z 2e and impurity Z 2b Reverse-phase high performance liquid chromatography. To ensure the feasibility of the method, according to the "Technical Guidelines for Validation of Analytical Methods for Quality Control of Chemical Drugs" [H] GPH5-1, the Chinese Pharmacopoeia 2020 Edition Part IV General Chapter 9101 "Guidelines for Validation of Analytical Methods" and the relevant requirements of ICH Q2 (R1), the specificity, system suitability, quantitative limit, detection limit, accuracy, durability, etc. were verified. The method validation showed that this method has high sensitivity, high accuracy, good reproducibility, and good durability, and is suitable for the detection of impurity Z in finerenone intermediate Z2. 2a , impurity SM1, impurity Z 1c 、Impurity Z 2d , impurity Z1, impurity Z 2e 、Impurity Z 2b Determination of.

[0099] In the present invention, the "test sample solution" refers to a solution whose main component is rupatadine fumarate SM2, such as rupatadine fumarate SM2 prepared by conventional methods known in the art. The test sample solution contains finerenone intermediate Z2 and impurity Z 2a , impurity SM1, impurity Z 1c , impurity Z1, impurity Z 2d 、Impurity Z 2e 、Impurity Z 2b Any one or more of .

[0100] In the present invention, the "test composition" refers to a composition comprising finerenone intermediate Z2, impurity Z 2a , impurity SM1, impurity Z 1c , impurity Z1, impurity Z 2d 、Impurity Z 2e 、Impurity Z 2b Any one or more of, and impurities SM3, impurities SM 3a 、Impurity Z 2c In addition, the composition to be tested may also contain other unspecified compounds, which refer to other impurities that may be introduced when synthesizing finerenone intermediate Z2 using conventional methods known in the art.

[0101] Unless otherwise specified, all numerical values ​​and similar values ​​of the expression parameters used in the present invention are understood to be modified by the term "about". That is, these numerical values ​​are allowed to have certain reasonable deviations or error ranges in practical applications, and do not have to strictly conform to the exact numerical values ​​given. Unless otherwise indicated, the numerical parameters described in the present invention are approximate values ​​that can be changed according to the performance required to be obtained.

[0102] Unless otherwise specified, the terms or phrases involved in the present invention should not be considered as uncertain or unclear without special definition, but should be understood according to the common meaning in the art. When a trade name appears in this article, it is intended to refer to the corresponding commodity or its active ingredient.

[0103] In the present invention, specificity, also known as selectivity or specificity, refers to the ability of the analytical method to accurately and selectively detect the component being measured when other components may be present in the sample. Specificity is a measure of mutual interference when the method is used for complex sample analysis. The present invention verifies whether the HPLC method has sufficient specificity to ensure accurate and unerring determination of the target analyte in complex samples.

[0104] In the present invention, the limit of detection (LOD) refers to the minimum concentration or amount of the target compound that the analytical method can reliably detect. The detection sensitivity of the HPLC method is determined, that is, the lowest concentration of the target analyte in the sample that can be identified. This helps to evaluate the reliability of the method at very low concentrations.

[0105] In the present invention, the limit of quantitation (LOQ) refers to the lowest concentration or content of the target compound that the analytical method can reliably quantify. The limit of quantitation reflects the ability of the analytical method to detect sensitive quantification and determines at what concentration the HPLC method can accurately and reliably quantify the target analyte.

[0106] In the present invention, accuracy refers to the closeness between the measurement result and the true value or reference value. In HPLC method validation, accuracy is usually determined by comparing the measurement result with a standard or reference substance of known concentration. Verifying the accuracy of the HPLC method, i.e., the consistency of the measurement result with the true value or reference value. This helps to ensure that the method can accurately reflect the actual content of the target analyte in the sample.

[0107] In the present invention, robustness refers to the degree to which the measurement results are not affected when there are small changes in the measurement conditions. It reflects the ability of the analysis method to resist interference from variable test factors.

[0108] In the present invention, the term "high performance liquid chromatography", also known as "high pressure liquid chromatography", "high speed liquid chromatography", "high resolution liquid chromatography", "modern column chromatography", etc., is a chromatographic analysis technology based on classical liquid chromatography and citing the theory of gas chromatography. High performance liquid chromatography (HPLC) uses liquid as the mobile phase and adopts a high-pressure infusion system to pump a single solvent with different polarities or a mixed solvent in different proportions, a buffer solution and other mobile phases into a chromatographic column equipped with a stationary phase. After the components in the column are separated, they enter the detector for detection, thereby realizing the analysis of the sample. This method can be used to separate, identify and quantitatively analyze various complex samples. High performance liquid chromatography is divided into normal phase chromatography and reverse phase chromatography according to the different polarities of the stationary phase and the mobile phase. The reverse phase HPLC method is a liquid chromatography system composed of a non-polar stationary phase and a polar mobile phase. It is the most important separation mode of liquid chromatography today and can be used for the separation of almost all organic substances that can be dissolved in polar or weak polar solvents.

[0109] In the present invention, the term "separation degree" refers to the ratio of the difference between the retention values ​​of two adjacent chromatographic peaks to half the sum of the low widths of the two chromatographic peaks. In order to judge the separation of two adjacent components in the chromatographic column, the separation degree (R) can be used as an indicator of the separation efficiency of the chromatographic column. Whether it is qualitative identification or quantitative determination, unless otherwise specified, the separation degree between the chromatographic peak of the substance to be tested and the adjacent chromatographic peak should not be less than 1.5.

[0110] In the present invention, the term "Signal-to-Noise Ratio" refers to the ratio between signal and noise. In HPLC quantitative analysis, the signal-to-noise ratio (S / N) is an important parameter to measure the sensitivity of the system, and is mainly used to evaluate the clarity and reliability of the analytical signal, guide quantitative analysis, and evaluate instrument performance. A high signal-to-noise ratio usually means that the accuracy of the quantitative analysis is higher, because the signal intensity is large and stable, which is conducive to accurately determining the concentration of the analyte.

[0111] In the examples of the present invention, information on the compounds involved is shown in Table 1.

[0112] Table 1 Summary of basic information of compounds

[0113]

[0114]

[0115] In the embodiment of the present invention, the determination is carried out according to high performance liquid chromatography (Chinese Pharmacopoeia 2020 Edition Four General Rules 0512). In the embodiment of the present invention, the solutions to be tested are all freshly prepared before use.

[0116] In the embodiment of the present invention, the main instruments and chromatographic conditions are shown in Table 2.

[0117] Table 2 Main instruments and chromatographic conditions

[0118]

[0119]

[0120] Table 3 Gradient elution program

[0121] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 80 20 3 80 20 27 62 38 45 40 60 50 40 60 50.1 80 20 60 80 20

[0122] In the embodiment of the present invention, the correction factor in the range of 0.9 to 1.1 is calculated as 1.0. 2e The actual calculated correction factor is 0.94, which is within the range of 0.9 to 1.1, so it is calculated as 1.0. For other related impurities, if the correction factor is not specifically stated, it is assumed to be 1.0.

[0123] Example 1

[0124] The present invention adopts reverse phase high performance liquid chromatography to detect the impurity Z in the finerenone intermediate Z2. 2a , impurity SM1, impurity Z 1c , impurity Z1, impurity Z 2d 、Impurity Z 2e 、Impurity Z 2b The specific method for separation and determination is as follows:

[0125] (1) Prepare the test solution

[0126] Solvent: 50% acetonitrile aqueous solution, prepared from acetonitrile and water in a volume ratio of 50:50.

[0127] Test solution: Take an appropriate amount of the product, weigh accurately, add solvent and sonicate to dissolve and dilute to make a solution containing about 1 mg per 1 ml.

[0128] Control solution: Accurately measure an appropriate amount of the test sample solution and add solvent to quantitatively dilute it to make a solution containing approximately 5 μg per 1 ml.

[0129] System suitability solution: Take Z2 system suitability reference substance (containing impurity Z 2a , impurity SM1, impurity Z 1c , impurity Z1, impurity Z 2d 、Impurity Z 2e 、Impurity Z 2b ) was added with a solvent and ultrasonically dissolved and diluted to make a solution containing about 1 mg per 1 ml.

[0130] (2) Chromatographic conditions

[0131] As shown in Table 2, octadecylsilane bonded silica gel is used as filler (Shim-pack FC-ODS 4.6mm×150mm, 3μm or chromatographic column with equivalent performance); 0.1% trifluoroacetic acid aqueous solution is used as mobile phase A, methanol is used as mobile phase B, and gradient elution is performed according to Table 3; the flow rate is 1.1ml / min; the column temperature is 35°C; the detection wavelength is 260nm; the injection volume is 10μl; and the injector temperature is 5°C.

[0132] (3) Detection

[0133] Accurately measure the system suitability solution, inject it into the liquid chromatograph, and record the chromatogram. In the chromatogram of the system suitability solution, the peak order is impurity Z 2a , impurity SM1, impurity Z 1c , Z2, impurity Z1, impurity Z 2d 、Impurity Z 2e 、Impurity Z 2b , the separation between each component peak should meet the requirements.

[0134] Accurately measure the test solution and the reference solution, inject them into the liquid chromatograph respectively, record the chromatogram, and calculate the content of each impurity by the principal component self-reference method with the addition of the correction factor. If there is an impurity peak in the chromatogram of the test solution, in addition to the blank solvent peak, the impurity Z 2a , impurity SM1, impurity Z 1c , impurity Z1, impurity Z 2b The corrected peak area (multiplied by the correction factors 1.2, 0.58, 1.5, 1.6, 1.2, respectively) shall not be greater than 0.3 times (0.15%) the main peak area of ​​the control solution. 2d 、Impurity Z 2eThe peak area shall not be greater than 0.3 times the main peak area of ​​the control solution (0.15%), the peak area of ​​other individual impurities shall not be greater than the main peak area of ​​the control solution (0.5%), and the total amount of impurities shall not exceed 2.0%. Any peak in the chromatogram of the test solution that is less than 0.1 times the main peak area of ​​the control solution can be ignored (0.05%).

[0135] Example 2. Specificity

[0136] (1) Prepare the test solution

[0137] Blank solvent: 50% acetonitrile aqueous solution, prepared from acetonitrile and water in a volume ratio of 50:50.

[0138] Impurity Z 2c Stock solution: Accurately weigh impurity Z 2c 10.41 mg, put in a 10 ml volumetric flask, first add 3 ml N, N-dimethylacetamide and dissolve in 80 ° C water bath, then add methanol to dilute to the scale, shake well, and you have it.

[0139] Impurity Z 2a Stock solution: Accurately weigh impurity Z 2a 10.59 mg, put in a 10 ml volumetric flask, first add 3 ml N, N-dimethylacetamide to dissolve, then add methanol to dilute to the scale, shake well, and you have it.

[0140] Impurity Z1 stock solution: Accurately weigh 10.76 mg of impurity Z1, place in a 10 ml volumetric flask, add methanol to dissolve and dilute to the scale, shake well, and obtain.

[0141] Impurity SM1 stock solution: Accurately weigh 10.66 mg of impurity SM1, place it in a 10 ml volumetric flask, add methanol to dissolve and dilute to the scale, shake well, and obtain.

[0142] Impurity Z 2d Stock solution: Accurately weigh impurity Z 2d 10.18 mg, put in a 10 ml volumetric flask, add methanol to dissolve and dilute to the scale, shake well, and you have it.

[0143] Impurity Z 1c Stock solution: Accurately weigh impurity Z 1c 10.50 mg, put into a 10 ml volumetric flask, add methanol to dissolve and dilute to the scale, shake well, and you have it.

[0144] Impurity Z 2b Stock solution: Accurately weigh impurity Z 2b 10.72 mg, put in a 10 ml volumetric flask, add methanol to dissolve and dilute to the scale, shake well, and you have it.

[0145] Impurity Z 2e Stock solution: Accurately weigh impurity Z2e 10.46 mg, put in a 10 ml volumetric flask, add methanol to dissolve and dilute to the scale, shake well, and you have it.

[0146] Impurity SM3 stock solution: Accurately weigh 10.74 mg of impurity SM3, place it in a 10 ml volumetric flask, add solvent to dissolve and dilute to the scale, shake well, and obtain.

[0147] Impurity SM 3a Stock solution: Accurately weigh the impurity SM 3a 7.57 mg, put into a 100 ml volumetric flask, add solvent to dissolve and dilute to the scale, shake well, and you have it.

[0148] Impurity Z2 stock solution: Accurately weigh 10.23 mg of impurity Z2, place in a 10 ml volumetric flask, add solvent to dissolve and dilute to scale, shake well, and obtain

[0149] Each impurity location solution: accurately pipette 0.15 ml of each impurity stock solution, place it in a 10 ml volumetric bottle, add solvent to dilute to the scale, shake well, and obtain. (Z 2a ,SM1,Z 1c , Z 2d , Z1, Z 2e , Z 2b , Z 2c , SM2)

[0150] SM3 positioning solution: Accurately pipette 0.15 ml of SM3 impurity stock solution into a 10 ml volumetric flask, add solvent to dilute to the scale, shake well, and obtain.

[0151] SM 3a Positioning solution: Precision pipetting of SM 3a Place 0.1 ml of impurity stock solution in a 100 ml volumetric flask, add solvent to dilute to the scale, shake well, and the solution is ready.

[0152] Mixed stock solutions of various impurities: Accurately pipette 0.15 ml (Z 2a ,SM1,Z 1c , Z 2d , Z1, Z 2e , Z 2b , Z 2c ), SM3 impurity stock solution 0.5ml, SM 3a Place 0.1 ml of impurity stock solution in a 10 ml volumetric flask, add solvent to dilute to the scale, shake well, and the solution is ready.

[0153] Test sample solution: Accurately weigh 25.11 mg of the test sample, place it in a 25 ml volumetric flask, add solvent, ultrasonically dissolve and dilute to the scale, shake well, and obtain.

[0154] Mixed solution: Accurately weigh 10.14 mg of the test sample and place it in a 10 ml volumetric flask. Accurately add 1 ml of the mixed stock solution of each impurity, then add the solvent to dissolve by ultrasonic and dilute to the scale. Shake well to obtain.

[0155] Self-control solution: Accurately pipette 0.5 ml of the test solution into a 100 ml volumetric flask, dilute to the mark with solvent, and shake well.

[0156] (2) Detection

[0157] Accurately measure 10 μl of each of the blank solvent, positioning solution, other impurity mixed positioning solution, test solution and mixed solution, and perform detection according to the chromatographic conditions of Example 1, and record the chromatogram.

[0158] The test results are shown in Table 4. Figure 1 to Figure 3 As shown, Figure 2 and Figure 3 The integration results are shown in Table 5 and Table 6. The data show that the blank solution does not interfere with the detection of related substances; the separation between the main peak and the adjacent impurity peak is greater than 1.5, and the separation between each known impurity peak is greater than 1.5, indicating that the detection of each impurity is not affected by the blank solvent, the main component and the known impurities SM3, SM 3a and impurity Z 2c There is no interference, that is, this method has good specificity.

[0159] Table 4 Specificity test results

[0160]

[0161]

[0162] Table 5 Figure 2 The integral result table

[0163]

[0164] Table 6 Figure 3 The integral result table

[0165]

[0166] Example 3. System Applicability

[0167] System suitability solution: Accurately measure 0.5 ml of the test solution under "Example 2. Specificity" and place it in a 100 ml volumetric flask. Add solvent to dilute to the scale and shake well.

[0168] Accurately measure 10 μl of the system suitability solution, inject it into the liquid chromatograph, and perform the test according to the chromatographic conditions of Example 1. Test 6 times continuously and record the chromatogram.

[0169] The test results are shown in Table 7. Figure 4 As shown, in the system suitability solution, the RSD of the main peak area was 0.3%, less than 2.0%, and the tailing factor and theoretical plate number met the requirements.

[0170] Table 7 System suitability test results

[0171]

[0172] Example 4. Limit of Quantitation

[0173] Quantitative limit solution 1: Accurately pipette 2.5 ml of the reference substance stock solution under "Example 6. Accuracy" into a 25 ml volumetric flask, dilute to the mark with solvent, and shake well to obtain.

[0174] Quantitative limit solution 2: Accurately pipette 0.5 ml of the Z2 stock solution under "Example 2. Specificity" into a 100 ml volumetric flask, dilute to the mark with solvent, and shake well to obtain.

[0175] Quantitation limit solution: Accurately pipette 1.6 ml of quantitation limit solution 1 and 0.4 ml of quantitation limit solution 2, place them in a 10 ml volumetric flask, dilute to the scale with solvent, shake well, and obtain.

[0176] The quantitative limit solution was sampled 6 times continuously, and the detection was performed according to the chromatographic conditions of Example 1. The ratio of the main peak height to the noise (signal-to-noise ratio) and the peak area RSD were calculated, and the chromatogram was recorded.

[0177] The formula for calculating the limit of quantitation is as follows:

[0178]

[0179] The test results are shown in Table 8. Figure 5 As shown, impurity Z 2a The quantitative limit concentration of impurity SM1 is 0.256 μg / ml, the concentration in the sample is 0.026%, the mean signal-to-noise ratio is 24.8, and the peak area RSD is 3.8%. The quantitative limit concentration of impurity Z is 0.246 μg / ml, the concentration in the sample is 0.025%, the mean signal-to-noise ratio is 21.8, and the peak area RSD is 4.1%. 1c The quantitative limit concentration of impurity Z1 is 0.251 μg / ml, the concentration in the sample is 0.025%, the signal-to-noise ratio is 21.0, and the peak area RSD is 3.7%; the quantitative limit concentration of impurity Z2 is 0.202 μg / ml, the concentration in the sample is 0.020%, the signal-to-noise ratio is 32.9, and the peak area RSD is 2.5%; the ... 2dThe quantitative limit of impurity Z was 0.226 μg / ml, the concentration in the sample was 0.023%, the mean signal-to-noise ratio was 30.3, and the peak area RSD was 2.0%. 2e The quantitative limit of impurity Z was 0.246 μg / ml, the concentration in the sample was 0.025%, the mean signal-to-noise ratio was 38.1, and the peak area RSD was 2.3%. 2b The quantitative limit concentration is 0.253μg / ml, the concentration in the sample is 0.025%, the signal-to-noise ratio is 34.3, and the peak area RSD is 1.5%. At the quantitative limit concentration of each impurity, the signal-to-noise ratio is greater than 10, and the peak area RSD is less than 10%, which meets the requirements for the determination of related substances, indicating that the impurity can be accurately quantified at this level.

[0180] Table 8 Quantitation limit test results

[0181]

[0182]

[0183] Example 5. Detection Limit

[0184] Detection limit solution: Accurately measure 3.5 ml of the quantitative limit solution, place it in a 10 ml volumetric flask, dilute to the scale with solvent, shake well, and obtain.

[0185] The above detection limit solution was sampled three times continuously, and the detection was performed according to the chromatographic conditions of Example 1, the ratio of the main peak height to the noise (signal-to-noise ratio) was calculated, and the chromatogram was recorded. The detection limit calculation formula is as follows:

[0186]

[0187] The test results are shown in Table 9. Figure 6 As shown, impurity Z 2a The detection limit concentration of impurity SM1 is 0.089 μg / ml, the concentration in the sample is 0.009%, and the signal-to-noise ratio is 7.5; the detection limit concentration of impurity Z is 0.086 μg / ml, the concentration in the sample is 0.009%, and the signal-to-noise ratio is 6.5; the detection limit concentration of impurity SM1 is 0.089 μg / ml, the concentration in the sample is 0.009%, and the signal-to-noise ratio is 7.5; 1c The detection limit concentration of impurity Z is 0.081μg / ml, the concentration in the sample is 0.008%, and the average signal-to-noise ratio is 5.5; the detection limit concentration of impurity Z2 is 0.071μg / ml, the concentration in the sample is 0.007%, and the average signal-to-noise ratio is 9.9; the detection limit concentration of impurity Z1 is 0.088μg / ml, the concentration in the sample is 0.009%, and the average signal-to-noise ratio is 6.3; impurity Z 2d The detection limit concentration is 0.079μg / ml, the concentration in the sample is 0.008%, and the average signal-to-noise ratio is 8.9; impurity Z 2eThe detection limit concentration is 0.086μg / ml, the concentration in the sample is 0.009%, and the average signal-to-noise ratio is 11.2; impurity Z 2b The detection limit concentration is 0.089μg / ml, the concentration in the sample is 0.009%, and the average signal-to-noise ratio is 10.1. The signal-to-noise ratio of the chromatographic peak of the detection limit concentration of each component is greater than 3, which meets the requirements for the determination of related substances, indicating that impurities can be effectively detected at this level.

[0188] Table 9 Detection limit determination results

[0189]

[0190] Example 6. Accuracy

[0191] (1) Prepare the test solution

[0192] Reference substance stock solution: Accurately measure impurity Z under "Example 2. Specificity" 2a ,SM1,Z 1c , Z 2d , Z1, Z 2e , Z 2b Place 1.5 ml of each stock solution in a 100 ml volumetric flask, dilute to the mark with solvent, shake well, and you are done.

[0193] Reference substance solution: Accurately measure 2.5 ml of reference substance stock solution, place in a 25 ml volumetric flask, dilute to the mark with solvent, shake well, and obtain.

[0194] Unspiked test sample solution: Same as the test sample solution under “Specificity”.

[0195] Spiked test sample solution 1#: Accurately weigh 25 mg of the test sample, place it in a 25 ml volumetric flask, add about 20 ml of diluent and ultrasonically dissolve it, then add 2.0 ml of the reference sample stock solution, dilute to the scale with solvent, shake well, and obtain; the sample weights are 25.76 mg, 25.33 mg, and 25.60 mg respectively.

[0196] Spiked test sample solution 2#: Accurately weigh 25 mg of the test sample, place it in a 25 ml volumetric flask, add about 20 ml of diluent and ultrasonically dissolve it, then add 2.5 ml of the reference sample stock solution, dilute to the scale with solvent, shake well, and obtain; the sample amounts are 25.89 mg, 25.12 mg, and 25.29 mg respectively.

[0197] Spiked test sample solution 3#: Accurately weigh 25 mg of the test sample, place it in a 25 ml volumetric flask, add about 20 ml of diluent and ultrasonically dissolve it, then add 3.0 ml of the reference sample stock solution, dilute to the scale with solvent, shake well, and obtain; the sample amounts are 25.43 mg, 25.22 mg, and 25.30 mg respectively.

[0198] Self-control solution: Accurately measure 0.5 ml of each test solution and place it in a 100 ml volumetric flask, dilute to the scale with solvent, shake well, and obtain.

[0199] (2) Detection

[0200] Accurately measure 10 μl of each of the blank solvent, reference solution, unspiked test solution, self-control solution, and spiked test solution, inject into a liquid chromatograph, detect according to the chromatographic conditions of Example 1, and record the chromatogram. Calculate the impurity content and recovery rate according to the external standard method and the self-control method with correction factor.

[0201] The test results are shown in Table 10. Figure 3 , Figure 7 to Figure 10 As shown, the recovery rate of each impurity was calculated by external standard method. 2a ,SM1,Z 1c , Z1, Z 2d , Z 2e , Z 2b The average recoveries were 99.8%, 102.7%, 96.6%, 101.2%, 101.5%, 99.6%, and 101.5%, respectively, and the RSD values ​​were all less than 5.0%. The recoveries of each impurity were calculated by the self-control method with the correction factor added. 2a ,SM1,Z 1c , Z1, Z 2d , Z 2e , Z 2b The average recoveries were 100.2%, 102.9%, 99.7%, 105.1%, 101.1%, 98.1%, and 101.0%, respectively, and the RSD values ​​were all less than 5.0%. The recovery rates of each impurity in the above two calculation methods were all between 90% and 108%, indicating that the accuracy of the determination of each impurity by the two methods met the requirements.

[0202] Table 10 Accuracy test results

[0203]

[0204]

[0205]

[0206]

[0207] Example 7. Chromatographic Conditions Robustness

[0208] Take the mixed solution under "Example 2. Specificity" and use normal chromatographic conditions and the following changed chromatographic conditions (mobile phase ratio ±2, flow rate ±0.1 ml / min, column temperature ±2°C, trifluoroacetic acid ±0.01%, initial organic phase ratio ±2%), respectively. After the instrument system is stable, test them separately and record the separation between each peak.

[0209] The results are shown in Table 11-Table 12. Figures 11 to 19 As shown in the figure, when the flow rate, column temperature, mobile phase ratio and trifluoroacetic acid ratio fluctuate, the peak order of each impurity and the main component remains unchanged; the separation degrees between each known impurity in the mixed solution are greater than 1.5, and the separation degrees between the main component and the adjacent impurities are greater than 1.5, which meets the detection requirements and has good durability.

[0210] Table 11 Chromatographic condition robustness - relative retention time

[0211]

[0212]

[0213] Table 12 Chromatographic Conditions Robustness - Separation

[0214]

Claims

1. A method for separating finerenone intermediate Z2 and its impurities by HPLC, characterized in that: The steps include: (1) preparing a sample solution to be tested; the sample solution to be tested comprises the finerenone intermediate Z2 and its impurities; the impurities include impurity Z 2a , impurity SM1, impurity Z 1c , impurity Z1, impurity Z 2d 、Impurity Z 2e 、Impurity Z 2b Any one or more of; (2) using octadecylsilane bonded silica gel as a chromatographic column filler, using trifluoroacetic acid aqueous solution as mobile phase A, using an organic solvent as mobile phase B, and separating the main component phenerenone intermediate Z2 and its impurities in the sample to be tested by gradient elution; The structural formula of the finerenone intermediate Z2 is shown in Formula I. 2a The structural formula of the impurity SM1 is shown in Formula II, the structural formula of the impurity Z is shown in Formula III, 1c The structural formula of the impurity Z1 is shown in Formula Ⅴ, and the impurity Z 2d The structural formula of is shown in Formula VI, the impurity Z 2e The structural formula of is shown in Formula VII, the impurity Z 2b The structural formula is shown in Formula VIII; 2. The method according to claim 1, characterized in that The sample to be tested is a composition to be tested; the composition to be tested comprises finerenone intermediate Z2, related substances, and impurity Z 2a , impurity SM1, impurity Z 1c , impurity Z1, impurity Z 2d 、Impurity Z 2e 、Impurity Z 2b Any one or more of; the related substances include impurities SM3, impurities SM 3a 、Impurity Z 2c Any one or more of; the structural formula of the impurity SM3 is shown in Formula IX, the impurity SM 3a The structural formula of is shown in Formula X, impurity Z 2c The structural formula is shown in Formula Ⅺ; 3. The method according to claim 1, characterized in that The program of the gradient elution was set as follows: 0min, the volume ratio of the mobile phase A to the mobile phase B is 70-90:30-10; 3min, the volume ratio of the mobile phase A to the mobile phase B is 70-90:30-10; 27min, the volume ratio of the mobile phase A to the mobile phase B is 55-65:45-35; 45min, the volume ratio of the mobile phase A to the mobile phase B is 30-50:70-50; 50min, the volume ratio of the mobile phase A to the mobile phase B is 30-50:70-50; 50.1min, the volume ratio of the mobile phase A to the mobile phase B is 70-90:30-10; 60min, the volume ratio of the mobile phase A to the mobile phase B is 70-90:30-10.

4. The method according to claim 1, characterized in that: The concentration of the trifluoroacetic acid aqueous solution is 0.05%-0.15%; and the organic solvent is methanol.

5. The method according to claim 1, characterized in that: The flow rate of the mobile phase is 0.8-1.5 ml / min; the column temperature of the chromatographic column is 30° C.-40° C.; and the injector temperature is 3° C.-7° C.

6. A method for identifying finerenone intermediate Z2 and its impurities, characterized in that: The method according to any one of claims 1 to 4 is used to separate the finerenone intermediate Z2 and its impurities; the finerenone intermediate Z2 and its impurities are separated ...

7. The method according to claim 6, characterized in that The detection wavelength of the detector is 240nm-280nm.

8. The method according to claim 6, characterized in that Taking finerenone intermediate Z2 as the reference peak, the peak with a relative retention time of 0.73±0.2 was judged to be impurity Z 2a The relative retention time of 0.84±0.2 was judged as impurity SM1, and the relative retention time of 0.93±0.2 was judged as impurity Z. 1c The relative retention time of 1.17±0.2 was judged as impurity Z1, and the relative retention time of 1.21±0.2 was judged as impurity Z 2d The relative retention time of 1.41±0.2 is judged as impurity Z 2e The relative retention time of 1.46±0.2 is judged as impurity Z 2b .

9. A method for determining finerenone intermediate Z2 and its impurities, characterized in that: The steps include: (1) separating and detecting the finerenone intermediate Z2 and its impurities using the method described in any one of claims 6 to 8 to obtain a chromatogram; (2) Based on the chromatogram obtained in step (1), the content of each impurity is calculated by peak area using the main component self-reference method with a correction factor and / or the external standard method.

10. The method according to claim 9, characterized in that The content of each impurity is calculated by the principal component self-comparison method with a correction factor; the impurity Z 2a The correction factor of impurity SM1 is 0.58, and the correction factor of impurity Z 1c The correction factor of impurity Z1 is 1.6, and the correction factor of impurity Z 2b The correction factor is 1.2, and the impurity Z 2d The correction factor is 1.0, and the impurity Z 2e The correction factor is 1.0.

Citation Information

Cited By

  • Method for separating, identifying and quantifying fenerenone Z3 and impurities thereof

    CN119738502A